Estradiol (E2): Normal Range by Cycle Phase, Menopause, and in Men

Estradiol in premenopausal women is made primarily by granulosa cells of the developing ovarian follicle. In men and postmenopausal women, the dominant source shifts to peripheral aromatization, adipose tissue converts androgens (testosterone, androstenedione) to estradiol via the aromatase enzyme. This is why obese men and postmenopausal women on testosterone therapy can develop high estradiol levels and gynecomastia.

Two main assay platforms exist:

• Direct immunoassay: the standard for most clinical use. Acceptable accuracy at premenopausal levels but unreliable below ~30 pg/mL. Should not be used to monitor postmenopausal women, men, children, or aromatase inhibitor therapy.
• LC-MS/MS (mass spectrometry): the gold standard. Accurate at low levels. Order when the answer matters: men, postmenopausal monitoring, children, aromatase inhibitor monitoring.

Cycle and life-stage dependent:

• Follicular phase (cycle days 1–13): 30–120 pg/mL. Lowest at menses, climbing as the dominant follicle matures.
• Mid-cycle peak (around day 13–14): 200–500 pg/mL. Triggers the LH surge.
• Luteal phase (cycle days 15–28): 70–250 pg/mL. Secondary peak from corpus luteum.
• Menses (day 1–5): 30–100 pg/mL.
• Postmenopausal: typically below 30 pg/mL (often below 10 on LC-MS/MS).
• Pregnancy first trimester: 200–4000 pg/mL.
• Pregnancy third trimester: 5000–25,000 pg/mL.
• Adult men: 10–40 pg/mL.
• Pre-pubertal children: below 15 pg/mL.

For fertility evaluation, the relevant test is "day 3 estradiol", drawn cycle days 2–4. Elevated day 3 estradiol (>80 pg/mL) suggests diminished ovarian reserve, with FSH artificially suppressed by the high estradiol.

Context determines whether a value is "high":

• Reproductive-age women: high estradiol mid-cycle is normal. High estradiol in the early follicular phase suggests diminished ovarian reserve. Persistently high estradiol with irregular cycles raises concern for granulosa cell tumor.
• Postmenopausal women: anything above ~30 pg/mL warrants explanation. Causes: HRT, obesity, ovarian or adrenal tumor, adrenal hyperplasia, exogenous estrogen exposure (creams, supplements). Also consider malignancy-related estrogen production.
• Men: above 40–50 pg/mL is high. Causes:
  • Obesity (peripheral aromatization).
  • Testosterone replacement (aromatization of exogenous testosterone).
  • Liver disease (impaired estrogen clearance).
  • Estrogen-secreting tumor (adrenal, testicular, hepatic).
  • Anabolic steroid use.
  • Klinefelter syndrome.
• Children: high estradiol may indicate precocious puberty or estrogen-secreting tumor.

Symptoms of estrogen excess in men include gynecomastia, decreased libido, and emotional lability. In women, persistent estrogen excess increases risk for endometrial hyperplasia and breast tissue effects.

Again, depends on context:

• Postmenopausal women: low is expected and normal. The job of HRT, when prescribed, is to bring estradiol back into a tolerable physiologic range, not to high-normal cycling levels.
• Reproductive-age women:
  • Hypothalamic amenorrhea (low body weight, overtraining, stress, eating disorders), low estradiol with low/normal LH and FSH.
  • Premature ovarian insufficiency, low estradiol with high FSH (typically >25), often before age 40.
  • Functional hypothalamic amenorrhea, usually reversible with restoration of nutrition and reduced stress.
  • Hyperprolactinemia, high prolactin suppresses GnRH and downstream estradiol.
  • Anorexia nervosa, severe, persistent estradiol suppression.
  • Pituitary disease.
• Men: very low estradiol (below ~10 pg/mL) on testosterone therapy with aromatase inhibitors is increasingly recognized as harmful, with bone loss, joint pain, and decreased libido. Some estradiol is essential for male health.

The bone-protective effects of estradiol in men are well established. The trend in androgen-replacement medicine is to allow physiologic estradiol rather than suppress it.

Estradiol means different things on different cycle days. For specific clinical questions:

• Ovarian reserve / fertility evaluation: day 2–4 ("day 3"), paired with FSH and AMH.
• Confirming ovulation timing: mid-cycle estradiol peak followed by LH surge.
• Confirming menopause: typically not done with estradiol alone. Sustained FSH >25 with low estradiol over months in a woman with amenorrhea makes the diagnosis.
• HRT monitoring: timing depends on formulation. Trough levels (just before next dose) for transdermal patches; mid-cycle for cyclical regimens.
• Aromatase inhibitor monitoring: order LC-MS/MS; immunoassays are too imprecise at the suppressed levels.
• Gender-affirming feminizing hormone therapy: typically targets premenopausal female range (100–200 pg/mL).
• Men on testosterone replacement: periodic estradiol checks if symptomatic for high estradiol; routine universal aromatase inhibition is not recommended.

• Postmenopausal woman with estradiol above 30 pg/mL not on HRT: investigate for ovarian, adrenal, or peripheral source.
• Man with estradiol above 50 pg/mL and symptoms (gynecomastia, low libido): evaluate for obesity, liver disease, exogenous use, or rarely tumor.
• Reproductive-age woman with persistently low estradiol and amenorrhea: workup for hypothalamic amenorrhea (energy availability, weight, stress), prolactinoma, premature ovarian insufficiency.
• Day 3 estradiol above 80 pg/mL: diminished ovarian reserve; FSH may look falsely normal.
• Precocious puberty in a child: pediatric endocrinology evaluation.
• Use LC-MS/MS, not immunoassay for any low-level estradiol question (men, postmenopause, children, AI monitoring).

• FSH: paired with estradiol on day 3 for ovarian reserve; rises in menopause and POI.
• LH: surge triggers ovulation; elevated in PCOS and menopause.
• Progesterone: luteal phase confirmation of ovulation.
• AMH: better ovarian reserve marker than day 3 FSH/E2 in many cases.
• Prolactin: workup of amenorrhea or low estradiol.
• TSH: thyroid disease causes menstrual irregularity.
• Total testosterone and SHBG: particularly for hyperandrogenism workup.